DDrare: Database of Drug Development for Rare Diseases

Searched query = "Eosinophilic granulomatosis with Polyangiitis", "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "Churg-Strauss syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Anti-thymocyte globulin; Azathioprine; Benralizumab; CYCLOPHOSPHAMIDE; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Cyclosporine; Filgrastim; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); HPC cell infusion; Human normal immunoglobulin; Hydroxychloroquine; Infliximab; L04AC06; MEDI-563; MEPOLIZUMAB; MESNA; Mepolizumab; Mesna; Methotrexate; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; NUCALA; Naltrexone; Naltrexone Hydrochloride; Nucala; Nucala 100 mg powder for solution for injection; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; Prednisolone; Prednisone; Prednisone, methylprednisolone,cyclophosphamides; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; RITUXIMAB; Rituximab; SB-240563; SB-240563 (mepolizumab)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03482479 (ClinicalTrials.gov)	February 4, 2019	22/3/2018	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis	Drug: Naltrexone Hydrochloride;Other: Placebo Comparator	University of Pennsylvania	NULL	Recruiting	18 Years	N/A	All	36	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03482479
(ClinicalTrials.gov)

February 4, 2019

22/3/2018

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis

Drug: Naltrexone Hydrochloride;Other: Placebo Comparator

University of Pennsylvania

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States